共 282 条
[11]
Escudier B(2011)Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification J Clin Oncol 29 2904-2342
[12]
Eisen T(2005)Risks and benefits of phase 1 oncology trials, 1991 through 2002 N Engl J Med 352 895-579
[13]
Stadler WM(2004)Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335-1795
[14]
Szczylik C(2009)An overview of small-molecule inhibitors of VEGFR signaling Nat Rev Clin Oncol 6 569-132
[15]
Oudard S(2007)Mechanisms of adverse effects of anti-VEGF therapy for cancer Br J Cancer 96 1788-363
[16]
Siebels M(2008)A quantitative analysis of kinase inhibitor selectivity Nat Biotechnol 26 127-82
[17]
Negrier S(2010)A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080 J Pharmacokinet Pharmacodyn 37 347-5465
[18]
Chevreau C(2009)Hypertension and proteinuria: a class-effect of antiangiogenic therapies Anticancer Drugs 20 81-671
[19]
Solska E(2008)Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase Clin Cancer Res 14 5459-384
[20]
Desai AA(2008)E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition Int J Cancer 122 664-1463